

Rubius Therapeutics Logo

Rubius Therapeutics to Announce Second Quarter 2018 Financial Results

August 21, 2018

CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, plans to report second quarter 2018 financial results on Friday, August 31, 2018.

The company will not be conducting a teleconference in conjunction with its financial results press release.

About Rubius Therapeutics

Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com or follow us on [Twitter](https://twitter.com/rubiustx).

Media Contact:

Dan Budwick
1AB, Inc.
+1 (973) 271-6085
dan@1abmedia.com

Investor Contact:

Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com



Source: Rubius Therapeutics